Akari Therapeutics (AKTX)

• Market cap: $25.2M
• 1 day: 2.52%
• 5 days: 0.52%
• 1 month: -22.6%
• 3 months: -34.41%
• 6 months: -29.64%
• Year to date: -36.03%
• 1 year: -76.69%
• 5 years: -97.85%
• 10 years: -99.8%
• Sector: Healthcare
• Industry: Biotechnology

About: Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Employees: 12

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

71% more capital invested

Capital invested by funds: $377K [Q1] → $644K (+$267K) [Q2]

36% more funds holding

Funds holding: 11 [Q1] → 15 (+4) [Q2]

1.71% more ownership

Funds ownership: 0% [Q1] → 1.71% (+1.71%) [Q2]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.6
• Avg. target: $3.3
• High target: $5

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Sean Lee	$1.6	Buy Reiterated	9 Sep 2025
Maxim Group Jason McCarthy	$5	Buy Initiated	18 Jul 2025